HC Wainwright raises Absci price target to $16
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a Buy rating on Absci and raised the price target from $8 to $16.

*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Absci (NASDAQ: ABSI) and raised the price target to $16. The previous target was $8. The rating update reflects increased confidence in the company's prospects.
Rating and Target Details
The analyst's decision to raise the price target underscores a positive outlook for Absci. The new target of $16 represents a significant increase from the prior level of $8.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $8 |
| New Price Target | $16 |
What specific catalysts or milestones does Absci need to achieve to justify the doubled price target?
How might this rating upgrade influence investor sentiment and trading volume for Absci in the short term?
Could this price target increase signal a broader trend of renewed optimism in the biotech sector?



























